天康生物
(002100)
| 流通市值：87.10亿 | | | 总市值：87.10亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,650,405,232.45 | 2,862,751,583.55 | 2,683,793,806.31 | 2,821,543,685.04 |
| 衍生金融资产 | 50,239,720 | 10,928,020 | - | 18,904,760 |
| 应收票据及应收账款 | 749,252,664.5 | 613,496,831.43 | 712,264,597.17 | 430,747,144.81 |
| 其中：应收票据 | 73,897,110.28 | 13,472,571.03 | 26,635,535 | 9,621,710.25 |
| 应收账款 | 675,355,554.22 | 600,024,260.4 | 685,629,062.17 | 421,125,434.56 |
| 应收款项融资 | 11,281,090.5 | 2,293,230.66 | - | 13,531,966.48 |
| 预付款项 | 862,495,429 | 316,219,930.34 | 484,523,803.75 | 386,570,734.63 |
| 其他应收款合计 | 371,108,008.04 | 283,766,948.98 | 256,002,959.81 | 259,136,883.32 |
| 存货 | 2,995,707,795.88 | 4,324,528,777.21 | 4,740,191,546.93 | 4,554,052,219.74 |
| 其他流动资产 | 414,372,439.29 | 483,235,341.59 | 479,926,462.27 | 475,883,910.96 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 9,115,407,832.64 | 8,897,743,168.88 | 9,357,175,806.52 | 8,960,844,383.94 |
| 非流动资产: | | | | |
| 长期股权投资 | 33,557,734.7 | 33,829,509.69 | 37,337,881.74 | 36,106,734.47 |
| 固定资产 | 5,810,834,455.61 | 5,275,821,292.65 | 5,225,077,026.3 | 5,333,720,373.83 |
| 在建工程 | 361,581,003.77 | 842,659,427.57 | 932,015,224.15 | 814,699,980.31 |
| 生产性生物资产 | 280,753,800.16 | 292,697,549.84 | 295,548,779.62 | 320,756,122.27 |
| 使用权资产 | 608,222,219.8 | 631,357,615.02 | 652,150,650.08 | 623,646,061.49 |
| 无形资产 | 389,627,564.51 | 385,712,786.27 | 384,783,780.2 | 360,842,665.61 |
| 开发支出 | 3,160,945.29 | 750,000 | 6,212,450.33 | 7,012,450.33 |
| 商誉 | 178,477,452.07 | 178,477,452.07 | 178,477,452.07 | 178,477,452.07 |
| 长期待摊费用 | 18,863,067.67 | 20,842,652.13 | 23,445,114.07 | 24,040,240.28 |
| 递延所得税资产 | 92,261,994.7 | 74,658,527.12 | 74,115,375.03 | 72,177,211.16 |
| 其他非流动资产 | 29,230,334 | 17,969,934 | 269,784 | 19,335,938.65 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 7,806,570,572.28 | 7,754,776,746.36 | 7,809,433,517.59 | 7,790,815,230.47 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 16,921,978,404.92 | 16,652,519,915.24 | 17,166,609,324.11 | 16,751,659,614.41 |
| 流动负债: | | | | |
| 短期借款 | 2,537,021,478.74 | 2,696,058,721.89 | 3,181,805,433.42 | 3,319,416,995.67 |
| 衍生金融负债 | - | - | 5,097,980 | - |
| 应付票据及应付账款 | 612,285,051.23 | 580,497,806.69 | 653,572,967.88 | 697,115,170.84 |
| 其中：应付票据 | 14,849,491.93 | 23,788,021.93 | 21,082,795 | 5,297,615 |
| 应付账款 | 597,435,559.3 | 556,709,784.76 | 632,490,172.88 | 691,817,555.84 |
| 预收款项 | - | - | - | 48,509.17 |
| 合同负债 | 735,335,510.43 | 498,671,966.26 | 481,412,258.93 | 440,234,597.22 |
| 应付职工薪酬 | 233,701,919.22 | 220,155,750.6 | 267,627,308.6 | 297,562,626.32 |
| 应交税费 | 33,920,966.77 | 9,101,896.72 | 40,715,078.58 | 31,778,985.49 |
| 其他应付款合计 | 769,957,597.07 | 693,751,266.93 | 693,290,420.67 | 731,348,837.22 |
| 一年内到期的非流动负债 | 1,090,031,838.11 | 1,602,065,146.92 | 1,705,759,482.17 | 1,488,373,925.56 |
| 其他流动负债 | 150,544,894.23 | 64,233,941.19 | 66,013,031.64 | 81,314,703.09 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 6,162,799,255.8 | 6,364,536,497.2 | 7,095,293,961.89 | 7,087,194,350.58 |
| 非流动负债: | | | | |
| 长期借款 | 1,639,514,970 | 1,480,680,000 | 1,560,100,974.71 | 1,225,360,197.17 |
| 租赁负债 | 480,087,220.34 | 494,538,627.12 | 409,415,192.49 | 362,927,544.01 |
| 递延收益 | 141,346,468.6 | 144,513,152.4 | 144,541,629.79 | 143,286,142.41 |
| 递延所得税负债 | 17,817,871.75 | 17,218,120.35 | 17,676,089.84 | 18,134,454.16 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 2,278,766,530.69 | 2,136,949,899.87 | 2,131,733,886.83 | 1,749,708,337.75 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 8,441,565,786.49 | 8,501,486,397.07 | 9,227,027,848.72 | 8,836,902,688.33 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,365,251,515 | 1,365,251,515 | 1,365,251,515 | 1,365,251,515 |
| 资本公积 | 3,942,211,071.58 | 3,942,211,071.58 | 3,942,211,071.58 | 3,942,211,071.58 |
| 其他综合收益 | 54,994,069.08 | 10,282,726.62 | -1,735,012.04 | 51,116,647.82 |
| 盈余公积 | 466,773,396.09 | 466,773,396.09 | 466,773,396.09 | 466,773,396.09 |
| 一般风险准备 | 3,854,383.76 | 3,854,383.76 | 3,854,383.76 | 3,854,383.76 |
| 未分配利润 | 1,112,741,515.88 | 823,800,049.29 | 635,457,361.8 | 581,393,600.95 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 6,945,825,951.39 | 6,612,173,142.34 | 6,411,812,716.19 | 6,410,600,615.2 |
| 少数股东权益 | 1,534,586,667.04 | 1,538,860,375.83 | 1,527,768,759.2 | 1,504,156,310.88 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 8,480,412,618.43 | 8,151,033,518.17 | 7,939,581,475.39 | 7,914,756,926.08 |
| 负债和股东权益合计 | 16,921,978,404.92 | 16,652,519,915.24 | 17,166,609,324.11 | 16,751,659,614.41 |
| 公告日期 | 2024-10-29 | 2024-08-29 | 2024-04-30 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |